{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:07:45Z","timestamp":1790564865926,"version":"4.1.0"},"reference-count":15,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacopsychiatry"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The United States Food and Drug Administration approved the xanomeline-trospium\n                    combination in September 2024 for treating schizophrenia, based in part on three\n                    double-blind, randomized placebo-controlled trials in adults with schizophrenia\n                    experiencing acute psychosis. This random-effects model pairwise meta-analysis\n                    of those three trials found that xanomeline-trospium was comparable to placebo\n                    in terms of all-cause discontinuation, discontinuation rate due to adverse\n                    events, Simpson\u2013Angus Scale score change, Barnes Akathisia Rating Scale score\n                    change, body weight change, body mass index change, blood pressure change, serum\n                    total cholesterol change, blood glucose change, QTc interval changes, and the\n                    incidence of headache, somnolence, insomnia, dizziness, akathisia, agitation,\n                    tachycardia, gastroesophageal reflux disease, diarrhea, increased weight, and\n                    decreased appetite. However, xanomeline-trospium was associated with a higher\n                    incidence of at least one adverse event, dry mouth, hypertension, nausea,\n                    vomiting, dyspepsia, and constipation, and increased serum triglyceride compared\n                    with placebo. Notably, xanomeline-trospium demonstrated superior efficacy than\n                    placebo in improving the Positive and Negative Syndrome Scale (PANSS) total\n                    score, PANSS positive subscale score, and PANSS negative subscale score.<\/jats:p>","DOI":"10.1055\/a-2506-7022","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T18:47:52Z","timestamp":1738176472000},"page":"249-254","source":"Crossref","is-referenced-by-count":4,"title":["Xanomeline-Trospium for Adults with Schizophrenia Experiencing Acute\n                    Psychosis: A Systematic Review and Meta-analysis of Safety and Tolerability\n                    Outcomes"],"prefix":"10.1055","volume":"58","author":[{"given":"Taro","family":"Kishi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine,\n                    Toyoake, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Citrome","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, New York Medical\n                    College, Valhalla, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Sakuma","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine,\n                    Toyoake, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Hamanaka","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine,\n                    Toyoake, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasufumi","family":"Nishii","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine,\n                    Toyoake, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Hatano","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapeutics and Informatics, Fujita Health\n                    University School of Medicine, Toyoake, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Okehazama Hospital, Toyoake, Aichi,\n                    Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youichi","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Nansei Hospital, Matsusaka, Mie,\n                    Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine,\n                    Toyoake, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02138-4","article-title":"Incidence, prevalence, and global burden of schizophrenia \u2013 data, with critical\n                    appraisal, from the Global Burden of Disease (GBD) 2019","author":"M Solmi","year":"2023","journal-title":"Mol Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41380-022-01832-z","article-title":"Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale\n                    and strategy for safe implementation","volume":"28","author":"G Wolf","year":"2023","journal-title":"Mol Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1001\/jamapsychiatry.2023.4353","article-title":"Pharmacologic treatment of schizophrenia beyond dopamine receptor blockade-Has\n                    its time come yet?","volume":"1","author":"C Correll","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","article-title":"Muscarinic acetylcholine receptor agonists as novel treatments for\n                    schizophrenia","volume":"179","author":"S M Paul","year":"2022","journal-title":"Am J Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for\n                    schizophrenia","volume":"384","author":"S K Brannan","year":"2021","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT\n                    (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a\n                    randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"I Kaul","year":"2024","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: A\n                    randomized clinical trial","volume":"81","author":"I Kaul","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"S R Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute\n                    treatment of adults with multi-episode schizophrenia: A systematic review and\n                    network meta-analysis","volume":"394","author":"M Huhn","year":"2019","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41537-024-00525-6","article-title":"Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results\n                    from three 5-week, randomized, double-blind, placebo-controlled, EMERGENT\n                    trials. Schizophrenia (Heidelb)","volume":"10","author":"I Kaul","year":"2024","journal-title":""},{"key":"ref14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.schres.2024.09.023","article-title":"A network meta-analysis of KarXT and commonly used pharmacological interventions\n                    for schizophrenia","volume":"274","author":"A C Wright","year":"2024","journal-title":"Schizophr Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic\n                    reviews","volume":"372","author":"M J Page","year":"2021","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"T R Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1517\/14656566.2011.626767","article-title":"On-label on the table: What the package insert informs us about the tolerability\n                    profile of oral atypical antipsychotics, and what it does not","volume":"13","author":"L Citrome","year":"2012","journal-title":"Expert Opin Pharmacother"}],"container-title":["Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2506-7022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:35:41Z","timestamp":1762299341000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2506-7022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":15,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2506-7022","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0176-3679","1439-0795"],"issn-type":[{"value":"0176-3679","type":"print"},{"value":"1439-0795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]}}}